Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study

Severe COVID-19 (coronavirus disease 2019) is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an interleukin-6 (IL-6) inhibitor effective in treating CRS secondary to chimeric antigen receptor T-cell (CAR T-cell) therapy. The efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Smoke, Steven M., Raja, Karan, Hilden, Patrick, Daniel, Nicole M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834231/
https://www.ncbi.nlm.nih.gov/pubmed/33338559
http://dx.doi.org/10.1016/j.ijantimicag.2020.106265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834231/
https://www.ncbi.nlm.nih.gov/pubmed/33338559
http://dx.doi.org/10.1016/j.ijantimicag.2020.106265

Ejemplares similares